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Abstract
Introduction:  Hereditary angioedema (HAE) is caused by mutations in the C1inh gene, leading to dysfunction of the 
C1-esterase inhibitor (C1-INH). C1-INH interacts with MASP-1 and MASP-2 proteases, participating in the mannan-bind-
ing lectin (MBL) pathway of complement activation. The aim of the study was to investigate the contribution of possible
changes in MBL/MASP-2 complex activity and Helicobacter pylori, hepatitis B virus (HBV), and hepatitis C virus (HCV)
infections to the severity and frequency of clinical symptoms of HAE.
Materials and Methods: The study was performed in 65 patients with HAE and 113 healthy persons. The parameters mea-
sured were C1-INH, C4, MBL concentration and MBL/MASP-2 complex activity, and serological markers of H. pylori, HBV,
and HCV infection. Scores for the frequency and severity of HAE symptoms were determined.
Results: HAE scores were significantly higher in patients whose C1-INH activity did not exceed 10% than in patients with
activity of 10–52% (p=0.016). No significant differences were found in the median levels of MBL concentration and
MBL/MASP-2 complex activity between patients and the control group. There was a slight association between contact with
H. pylori in patients and HAE symptom score (p=0.052, not significant). Adult patients showed a 2.6-times higher frequen-
cy of anti-HBc than the general population. HBV DNA was negative in anti-HBc(+) patients.
Conclusions: These results suggest that the MBL complement activation pathway itself does not contribute to the frequency
of angioedema attacks. Infections with H. pylori and HBV may slightly influence the disease score (not significant).
Key words: hereditary angioedema, C1-inhibitor, mannan-binding lectin complement pathway, H. pylori, hepatitis B and
C infections.
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INTRODUCTION
Hereditary angioedema (HAE) is a rare primary
immunodeficiency disorder clinically characterized by
self-limiting, recurrent, acute, non-allergic edematous
episodes of the face, extremities, trunk, larynx, gastroin-
testinal tract, and/or genitals. The disease is caused by
mutations (e.g. point mutations, deletions, partial dupli-
cations) in the gene of the C1 esterase inhibitor 
(C1-INH) [8], leading to reduced synthesis or loss of bio-
logical function. Angioedema may be caused by a partial
deficit of C1-INH (type 1) or the presence of normal or
excessive amounts of this regulatory protein with
impaired function (type 2) [2, 24]. C1-INH deficiency
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(CP) of complement and bradykinin, a factor having
potent vasodilatory activity. Bradykinin is considered
today as the major mediator of edema in HAE [7, 13].
Indeed, elegant studies by Zahedi et al. [29] strongly sug-
gest that activation of the complement system alone
(without involvement of the contact system) does not
cause angioedema. It is believed, however, that external
factors, such as surgical procedures, physical and psychi-
cal trauma, tissue injury, and/or infections leading to the
activation of complement, contact, and/or fibrinolytic
cascades may cause C1-INH consumption [2]. These
triggers may result in an overwhelming, acute generation
of vasoactive peptides such as bradykinin [2, 7, 13].
Mannan-binding lectin (MBL) is generally known as
a pattern-recognition molecule protecting the host from
infection by direct opsonization of microorganisms or by
microbial lysis through complement activation [5, 20,
23]. The C1-INH molecule is also supposed to regulate
the MBL pathway via inhibition of MBL-associated ser-
ine proteases (MASPs), of which MASP-2 cleaves C4
much more efficiently than C1s does [22]. Thus MBL
pathway overactivation leading to C1-INH consumption
by MASPs might be one of the factors modifying HAE,
i.e. it may influence the age of onset of the first mani-
festation as well as the frequency and/or severity of
attacks. Furthermore, assessment of MBL-lectin path-
way parameters was undertaken to analyze whether
MBL deficiency, by contributing to increased suscepti-
bility to numerous infectious diseases [3, 4, 15, 16, 19,
27], might be associated with the frequency and severity
of edematous attacks.
As mentioned, factors such as infections may cause C1
inhibitor consumption. In fact, an influence of common
infections, such as by Helicobacter pylori (H. pylori), on the
frequency and severity of HAE attacks was observed [9].
As has been reported, successful eradication of H. pylori
resulted in a fivefold reduction in or complete disappear-
ance of HAE symptoms [9]. Many infectious diseases
resulting in enhanced antibody response and the forma-
tion of immune complexes may trigger the overuse of
already reduced C1-INH [2, 9, 10]. Therefore the second
objective of this study was to investigate whether exacer-
bations of acute HAE could be initiated by stimulation of
the immune response by infectious agents, leading to com-
plement activation and depletion of C1-INH. Infections
with H. pylori, hepatitis B (HBV), and hepatitis C (HCV)
were investigated for their possible contribution to edema
frequency or severity in HAE patients.
MATERIALS AND METHODS
Patients
Patients were diagnosed according to the criteria
proposed by Cicardi and Zingale[6]. Serum and plasma
samples from 65 patients were investigated. The sam-
ples were taken during remission of symptoms. The
patients were 19 children (age range: 4.5–18 years,
median: 12 years) and 46 adults (age range: 19–74 years,
median: 36 years). Sixty patients belonged to 28 fami-
lies, four patients were cases without a family history,
and one patient had two family members with abdomi-
nal symptoms but samples from them were not available
for laboratory testing. The clinical symptoms most often
observed were edema of the skin and subcutaneous tis-
sues, mucous membranes of the gastrointestinal tract,
and genitals, as well as of the brain (rather in children),
pharynx, and larynx. Brain involvement manifested as
insomnia, headaches, and temporary unconsciousness.
Sixty-one patients suffered from type 1 HAE and
two children and two adults (three of whom belonged to
one family) were diagnosed with type 2. Approval of the
Ethics Commission of the Child Health Memorial
Hospital and informed patient consent were obtained.
Reference group
Healthy children (n=33, age range: 1–16 years,
median: 7 years), receiving no medication and attending
the hospital for reasons unconnected with infections or
edema, were included in the control group for the MBL
study. Blood was taken during the control examination.
Samples from adult blood donors (n=80, age range:
18–65 years, median: 28 years) who had a medical exam-
ination at the Institute of Hematology, Warsaw, were
taken for comparison of MBL level and activity. The ref-
erence group for the study of anti-H. pylori IgG anti-
bodies were 636 children aged 10–12 years, unselected
for health status [17]. For the study of anti-H. pylori IgG
antibodies in adults, the reference group consisted of
3307 persons representing the Polish population [17].
Symptom scores
The severity score of HAE symptoms (1–6) was
defined as: 1–2 with few signs (e.g. small edema of extrem-
ities), 3–4 with medium signs (edema of different parts of
the body, gastrointestinal tract involved), and 5–6 with
severe edemas of several organs, involving the brain and
larynx being frequent and life-threatening. Symptoms were
further evaluated by a frequency score (1–6), i.e. 1 with
attacks once a year, 2 every 6 months, 3 every 3 months, 4
every 2 months, 5 every month, and 6 every week.
Treatment
Of the 19 C1-INH-deficient children described in this
paper, 11 were not being treated because of lack of
symptoms. The rest were on maintenance treatment with
ε-aminocaproic acid (EACA), with a combination of
EACA and danazol (100–200 mg/daily), or with tranex-
amic acid. Of the 46 C1-INH-deficient adult subjects, 14
were not being treated (one with type 2) because of no or
mild symptoms. Of the remaining 32 persons (one with
type 2), the majority received danazol alone (n=24) or in
combination with tranexamic acid (n=2). Five patients
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(n=2). One patient received intravenous infusions of
C1-INH concentrate twice (1000 U each time, Berinert);
the blood sample was taken after half a year. 
Assessment of C1-INH and C4
This was performed in sera by the nephelometric
method using a BN Prospec nephelometer (Dade
Behring, Germany). Activity of C1-INH esterase was
measured by the photometric method using a Techno-
chrome C1-INH Kit (Technoclone GmbH, Vienna,
Austria). The result was expressed as the percentage of
the normal human serum activity [18]. The reference
values applied for serum samples from healthy persons
were C1-INH (antigen): 0.20–0.32 g/l, C1-INH (activi-
ty): 70–130%, and C4: 0.15–0.55 g/l. The Department of
Clinical Microbiology and Immunology, Child Health
Memorial Institute, Warsaw, took part in the external
quality testing of C1-INH, coordinated by the Central
Laboratory for Blood Transfusion (Sanquin Blood
Supply Foundation, Amsterdam, Netherlands).
Determination of MBL concentration in sera 
and MBL/MASP-2 complex activity
MBL concentrations were determined using ELISA as
previously described [4]. Activity of the MBL/MASP-2
complexes was assessed by C4 deposition and was essen-
tially performed as described elsewhere [4]. A high-ionic-
strength buffer was used to exclude CP activation [21]. The
results depend on MBL/MASP-2 complex concentrations
and arrangement, but they do not depend on C4 or C1-
-INH serum levels/activity [25]. Thus they reflect MASP-
-2’s potency to cleave C4. Such a procedure avoids the
effect of C1-INH deficiency as well as the consumption of
endogenous C4 and other complement system factors.
Investigation of HBsAg and antibodies specific 
to infectious agents
Serological markers of HBV and HCV infection, i.e.
HBsAg and IgG anti-HBc and anti-HCV antibodies,
were determined by the respective Microparticle assays
AXSYM (Abbott, IL, USA) according to the manufac-
turer’s instructions. Measurement of anti-H. pylori was
performed by ELISA (Mikrogene, Germany). Positive
results for IgG anti-H. pylori antibodies were >24 U/ml,
the gray zone was 20–24 U/ml, and negative results were
<20 U/ml.
Investigation of HBV-DNA
HBV-DNA was searched for using the commercially
available, semi-automated HBV-DNA PCR assay
(Cobas Amplicor HBV Monitor, Roche Diagnostic
Systems, USA) according to the manufacturer’s instruc-
tions. The limit of detection was 200 copies per ml of
HBV-DNA and each run included appropriate positive
and negative controls according to the test requirements.
Statistical analysis
Median serum MBL concentrations, MBL pathway
activity, symptom scores, and C4 levels between the var-
ious groups were compared with the Mann-Whitney 
U-test (rank test) because of the lack of a normal distri-
bution. The Bonferroni correction was used for the
analysis of C1-INH (antigen and activity) and C4 levels
in the treated and untreated patients. The procedure for
applying the Bonferroni correction was to calculate the
p-values, multiply them by the number of tests, and set
values below 0.05 as significant, which is equivalent to
division of the level of significance by the number of
tests. Correlations between analyzed parameters were
assessed using Spearman’s correlation coefficient and
the test of its significance. p Values <0.05 were consid-
ered statistically significant. 
RESULTS
Complement components and scores of HAE symptoms
Table 1 lists the laboratory parameters of the
patients. Values of the C4 component in untreated and
M. Cedzyński et al.: Evaluation of factors modifying HAE 71
Table 1. C1-INH concentration, C1-INH activity, and C4 concentration in children and adults with type 1 and type 2 HAE 
Group examined C1-INH, g/l C1-INH activity,  C4, g/l
median (range) % median (range) median (range)
Children with type 1, 0.08 (0.02–0.43) 10% (5–43) 0.06 (0.01–0.11)
untreated (n=11)
Children with type 1, 0.045 (0.03–0.08) 7% (0.1–18) 0.05 (0.04–0.05)
treated (n=8)
Adults with type 1, 0.065 (0.02–0.27) 11% (0.1–34) 0.075* (0.01–0.15)
untreated (n=13)
Adults with type 1, 0.065 (0.03–0.24) 10% (0.1–40) 0.05* (0.01–0.11)
treated (n=31)
Patients with type 2a 0.41–0.69 (range) 10–34% (range) 0.04–0.10 (range)
a Two children and two adults; * p<0.05, after Bonferroni correction p>0.05.
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jects. The difference was significant (p<0.05; after
Bonferroni correction, p became >0.05). There was
a strong positive correlation between C1-INH antigen
concentration and C1-INH activity (Spearman’s corre-
lation test, r=0.57, p<0.01) and negative correlations
between these and the score of severity of symptoms
(r= –0.33, p=0.01 and r= –0.31, p=0.02), respectively.
Also, the score of frequency of symptoms correlated
with the score of their severity and with the C1-INH
antigen concentration (r=0.57 and r= –0.37, p<0.01 in
both cases).
It should be stressed that the disease symptom score
was usually higher in individuals in whom C1-INH activ-
ity did not exceed 10% (median: 5, mean: 4.5) than in
persons with this activity over 10% (median: 3, mean:
3.4; p<0.05). When C4 concentrations, as expressed in
mg/dl, were compared between individuals with juvenile
type I HAE onset (below 10 years) and those in whom
the first symptoms manifested after the age of 10 years,
a significant difference was noted (medians: 5.25 and
6.5, means: 5.08 and 6.72 mg/dl, respectively, p<0.05).
In contrast, the groups so defined did not differ signifi-
cantly in C1-INH activity.
MBL concentration, MBL/MASP-2 complex activity, 
and C4 concentration
MBL concentration and MBL pathway activity were
measured in 178 subjects. These were 52 children (19
HAE patients and 33 controls) and 126 adults (46 HAE
patients and 80 controls). The results are summarized in
Table 2. These data show that there were no statistical-
ly significant differences in MBL concentration and
MBL pathway activity between the healthy controls and
the C1-INH-deficient individuals. Moreover, no differ-
ences were found when both groups were subdivided
into children and adults (data not shown). Four C1-
-INH-deficient and four healthy persons were found to
be MBL deficient (MBL serum concentration below 100
ng/ml). The clinical symptom scores of the MBL-defi-
cient patients were between 1–6 and did not differ from
those of C1-INH-deficient individuals without MBL
deficiency. As expected, there was a strong positive cor-
relation between MBL protein concentration and MBL
protein activity (Spearman’s correlation test, r=0.82,
p<0.01 in C1-INH-deficient and r=0.87, p<0.01 in
healthy persons).
We also compared the values for C1-INH biological
activity with those for MBL pathway activity in each
patient, but no correlation was observed (r= –0.08,
p=0.56; Fig. 1).
Investigation of possible disease-modifying factors:
the role of infections
These examinations were performed in 19 children
and 42 adults. The results are summarized in Table 3.
IgG antibodies to H. pylori were found in 8/19 children
(42.1%) and in 23/42 adults (54.8%). The median value
of antibodies in children was 1560 U/ml (range:
51–3000) and in adults 134 U/ml (range: 24–2060). The
high level of antibodies (above 1500 U/ml) in 5 children
and 4 adults is worth noting. The children with high val-
ues of IgG antibodies were in the age range of 5–17
years and four were <10 years. In the reference groups
the presence of anti-H. pylori antibodies in 636 children
was 31.5% and in 3307 adults 84.2%. The difference
between children with HAE and those in the reference
group was not significant (p=0.33).
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Table 2. MBL and MBL pathway parameters in children and
adults
Group MBL  concentration MBL  pathway
examined (ng/ml) activity (mU)
Healthy controls (n=113)
median 774 432
range 24–4016 11–2459
1st–3rd quartile 360–1429 183–758
C1-INH-deficient individuals (n=65)
median 574 343
range 27–2057 15–2192
1st–3rd quartile 307–1111 181–758
p value* 0.11 0.94
*Median of healthy controls vs. median of patients.
Fig. 1 Lack of correlation between C1-INH biological activity and
complement MBL pathway activity. 
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Table 3. Detection of anti-H. pylori antibodies and hepatitis B
and hepatitis C serum markers in children and adults suffer-
ing from HAE
Group Age  Anti-
HBsAg Anti-HBc Anti-
(years) -H. pylori IgG -HCV
IgG
Children median 42.1% 0 5.3% 0
n=19 12 (8/19) (1/19)
Adults median 54.8% 0 16.7% 0
n=42 39 (23/42) (7/42)
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was accompanied by a higher score of HAE symptoms
(median: 5, mean: 4.8 in positive vs. median: 4, mean:
3.8 in negative persons). The difference was of border-
line significance (p=0.052).
No serological markers of ongoing HBV and HCV
infection were found in the studied individuals: HBsAg
and anti-HCV antibodies were negative in all the cases.
However, positive anti-HBc results were noted in 1/19
children (5.3%) and 7/42 adults (16.7%). Together, of
61 persons checked for hepatitis B and C markers, 8
(13.1%) showed anti-HBc antibodies. The 8 samples
from patients positive for anti-HBc (one child and 7
adults) were tested for the possible presence of HBV
DNA. All the samples proved to be negative. We com-
pared the score of clinical symptoms between HAE
patients negative and positive for anti-HBc antibodies.
Although the anti-HBc(+) patients tended to have
higher scores of severity than anti-HBc(–) patients, the
difference was not significant (p=0.1). 
DISCUSSION
Hereditary angioedema is a rare (1:10000 to 1:50000
live births) but dangerous disease, which may be life
threatening. Thus knowledge concerning various factors
potentially influencing the frequency and severity of
attacks is important. This study involved a relatively
large group of HAE patients with C1-INH deficiency
(n=65). The MBL complement activation pathway, sim-
ilarly to the classical one, is possibly regulated by C1-
-INH, interacting with MASPs, being homologues of
C1r/C1s. Moreover, both produce the same C3 conver-
tase (C4b2a). Activation of the MBL pathway might
therefore be an additional element which could worsen
the status of persons with HAE and/or, due to C1-INH
consumption, contribute to triggering attacks.
In the present study we compared MBL concentra-
tion and its ability to activate complement in C1-INH-
-deficient persons and a control group. No significant
differences in median MBL concentrations and
MBL/MASP-2 complex activities were found between
patients and controls (Table 2). Thus our results, in gen-
eral, may suggest that the MBL complement activation
pathway itself does not contribute to the frequency and
severity of attacks of HAE. It should be stressed that the
assay system applied excluded the interference of
endogenous C4 and C1-INH and thus reflected the
activity of MBL/MASP-2 complexes. In consequence,
the activation observed depended on MBL/MASP-2
complex concentration and arrangement (oligomeriza-
tion, MASP content), reflecting the fact that the poten-
tial ability of the serum to initiate the MBL pathway did
not correlate with C1-INH activity in patients. In con-
trast, in healthy subjects an active C1-INH protein reg-
ulates complement activity in vivo, so the serum poten-
cy determined in vitro may be higher due to the exclu-
sion of endogenous C1-INH action. Thus the value
determined in a patient may reflect a higher in vivo com-
plement activation level than in a representative of the
control group.
Another approach to studying the relationship of the
contribution of the lectin pathway compared with the
CP in HAE patients is to measure all the pathways
simultaneously. Hungarian colleagues used this
approach in 96 HAE patients and 30 healthy controls in
whom MBL genotypes were also determined [28]. In
their study, low MBL pathway activity in patients com-
pared with controls was found. These authors, however,
used another methodology which did not enable the
exclusion of an influence of endogenous C4 and C1-
-INH and, because of that, their results are difficult to
compare with ours. It seems to be reasonable, however,
that the data presented by Varga et al. [28] and in our
paper do not conflict due to the described reasons. The
activity of the CP correlated with the MBL pathway, but
not with that of the alternative pathway in HAE
patients’ sera. Activity of the MBL pathway was lower in
patients with onset of symptoms before the age of 10
years compared with those with onset over that age.
It was demonstrated that infection with H. pylori
increases the susceptibility of HAE patients to attacks of
angioedema [9, 10]. Eradication of the infection caused
a substantial decrease in attacks, especially of the bowel,
in most of the patients [10]. Our study adds new data to
these findings, concerning another population. The fre-
quency of anti-H. pylori IgG antibodies in the HAE chil-
dren (42.1%) differed slightly (not significantly) from
that in children of the general Polish population (31.5%,
p=0.33) [17]. The frequency of antibodies in adult
patients corresponded to that in the general population
[17]. The data from our study show that there was
a slight association only between H. pylori infection and
HAE appearance and/or intensity of symptoms. Thus it
appears that the findings presented by the Hungarian
authors, although spectacular, were probably exception-
al and not completely confirmed in our investigation [9].
Hepatitis B and hepatitis C are relatively common
viral infections in Poland, with a changing pattern, i.e.
a constant increase in the proportion of HCV (0.8%
HBsAg and 1.4% anti-HCV in the general population)
[11, 14]. Well-documented papers showed both HBV
and HCV to form immune complexes in chronically
infected patients [1, 26]. Immune complexes of these
viruses may affect the CP of complement, leading to
a further reduction in C1-INH in HAE patients. In this
study we did not find carriers of HBsAg or anti-HCV
antibodies among the investigated patients, while IgG
anti-HBc antibodies were found in 5.3% of the C1-INH-
-deficient children and 16.7% of adults, respectively
(Table 3). The presence of anti-HBc shows a previous
contact with HBV. It appeared that adult C1-INH-defi-
cient individuals showed a frequency of anti-HBc anti-
bodies that was 2.6-times higher than in the general
Polish population (6.2%, p<0.02) [11]. This may partly
be explained by the fact that patients with HAE might
be exposed to medical procedures such as blood sam-
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samples was HBV-DNA detected. Thus it appears that
some of our HAE patients had had contact with HBV,
but did not have apparent infection, as evidenced by
PCR. All our patients were negative for anti-HCV. We
should stress that negative results for contact with HCV
reflect the careful checking of products given to HAE
patients [12].
In conclusion, our results indicate that MBL protein
concentration and/or activity do not influence the score
of angioedema attacks in patients with HAE. Of the
infections studied there may be a slight association
between contact with H. pylori in children and score of
symptoms (not significant). Furthermore, we did not
find HBV carriers or HCV-infected persons in our
patient group, which would have enabled analysis of the
influence of these infections, but the increased frequen-
cy of anti-HB core antibodies in adult HAE patients in
comparison with the general population may be mean-
ingful.
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